The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition.
This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production. This treatment strategy is used in several immune mediated inflammatory diseases such as rheumatoid arthritis and small vessel vasculitis. The immune related adverse events associated with immune checkpoint inhibition resemble immune mediated inflammatory diseases. Here, we report a lower incidence of hypothyroidism in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. This letter aims to increase awareness of the immune related adverse events associated with immune checkpoint inhibition in future clinical trials of immune checkpoint inhibition together with B cell depletion (primarily trials of B cell lymphomas). Hopefully, observations from these clinical trials can guide future treatment strategies to treat or prevent immune related adverse events associated with immune checkpoint inhibition.
['Risbjerg|Rasmus Strøm|RS|', 'Hansen|Mie Vennize|MV|', 'Sørensen|Anne Sofie|AS|', 'Kragstrup|Tue Wenzel|TW|0000-0002-6439-397X']
B cell depletion Immune related adverse events Immune checkpoint inhibition Immune mediated inflammatory disease Hypothyroidism